Contact: Jeff Ezell
Mississauga, ON (September 28, 2009) – BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today that it received a Health Canada medical device license for the BD FocalPoint™ GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using BD SurePath™ Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
“We are confident that the BD FocalPoint GS Imaging System will provide cytology labs in Canada with an innovative tool to improve cervical cancer detection and enhance their productivity,” said Mike Oliver, Country General Manager of BD - Canada. “It demonstrates BD’s commitment to providing innovative, world-class products and services to help improve women’s health.”
Cervical cancer is the thirteenth most common cancer among Canadian women of all ages. Despite significant improvements in cervical cancer screening over the past 40 years, approximately 1,300 Canadian women were diagnosed with invasive cervical cancer in 2008, and an estimated 380 Canadian women died from this disease in the same year.
The key to detecting cervical cancer early is regular Pap testing. However, limitations exist with current technologies. Approximately one-third of Pap smear false negatives can be attributed to screening and interpretive errors in which abnormal cells are incorrectly classified.
The new BD FocalPoint GS Imaging System seeks to address this problem by offering laboratories key advantages over current cervical cancer imaging systems. Its state-of-the-art guided screening technology helps rapidly relocate the fields of view that the system has identified as the most likely to contain cells of interest.
 Public Health Agency of Canada. (2009, March, 2). Cervical cancer. Retrieved September 17, 2009 from http://www.phac-aspc.gc.ca/cd-mc/cancer/cervical_cancer-cancer_du_col_uterus-eng.php